Design of compounds having enhanced tumour uptake, using serum albumin as a carrier—part II. In vivo studies
- 31 August 1992
- journal article
- Published by Elsevier in International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology
- Vol. 19 (6) , 685-695
- https://doi.org/10.1016/0883-2897(92)90103-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and StrategiesJNCI Journal of the National Cancer Institute, 1989
- Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agentAnalytical Biochemistry, 1988
- Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancerInternational Journal of Cancer, 1988
- 125I-glycoconjugate labels for identifying sites of protein catabolism in vivo: Effect of structure and chemistry of coupling to protein on label entrapment in cells after protein degradationArchives of Biochemistry and Biophysics, 1985
- Visualization of the hepatic low-density lipoprotein receptor in rats by sequential scintiscansFEBS Letters, 1985
- Selective delivery of cytotoxic compounds to cells by the LDL pathwayJournal of Medicinal Chemistry, 1984
- A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivoBiochemical Journal, 1983
- Identification of the sites of albumin catabolism in the ratArchives of Biochemistry and Biophysics, 1981
- Albumin Metabolism in Neoplastic DiseasesScandinavian Journal of Clinical and Laboratory Investigation, 1968
- The Theory of Tracer Experiments with 131I-Labelled Plasma ProteinsPhysics in Medicine & Biology, 1957